Welcome to an enlightening session with top ophthalmology experts who will dive deep into the real-world data of Vabysmo use in everyday clinical settings. This webinar is designed for healthcare professionals seeking to enrich their understanding and optimize their approach to treating nAMD and DME. Through engaging presentations and discussions led by field leaders, you will gain exclusive insights into patient outcomes, clinical experiences and pioneering research.

Opening Remarks
Introduction to the Webinar objectives and a brief intro presentation
Speaker: Nancy Holekamp, MD
- - - - - - - - - -
Section I: Let's exchANGe learnings and experience from VABYSMO usage in naive patients

1. Vabysmo treatment in naive DME and nAMD patients - overview of real world data
Presentation of real-world data outcomes in naive patients in Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) from a UK center’s perspective.
Speaker: Professor Ian Pearce

2. Presentation of patient case
Naive patient case from Eye Hospital, UMC Ljubljana
Speaker: Professor Polona Jaki Mekjavić

3. Discussion
Interactive session with Q&A, sharing experiences and addressing queries from attendees.
- - - - - - - - - -
Coffee Break
- - - - - - - - - -
Section II: Let's talk about chANGe

1. Vabysmo treatment in switched DME and nAMD patients - overview of real world data
Presentation of Real world data and patient outcomes after switching to Vabysmo.
Speaker: Professor Anat Loewenstein

2. Presentation of patient case
Switch patient case from Eye Hospital Svjetlost (Croatia)
Speaker: Professor Ratimir Lazić

3. Discussion
Interactive session with Q&A, sharing experiences and addressing queries from attendees
- - - - - - - - - -
Closure
Closing remarks and summary of the day's insights by Nancy Holekamp
- - - - - - - - - -
Register now! Don’t miss this opportunity to connect with peers and learn from seasoned professionals about the transformative impacts of Vabysmo in contemporary clinical  practice. Register now to secure your spot in this must-attend event for forward-thinking ophthalmologists and researchers.
- - - - - - - - - -

▼ Produkt leczniczy jest dodatkowo monitorowany. Umożliwi to szybkie zidentyfikowanie nowych informacji o bezpieczeństwie. Osoby należące do fachowego personelu medycznego powinny zgłaszać wszelkie podejrzewane działania niepożądane. Zgłoszenia działań niepożądanych należy przekazywać do: Departamentu Monitorowania Niepożądanych Działań Produktów Leczniczych Urzędu Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, Al. Jerozolimskie 181 C, 02-222 Warszawa, tel.: + 48 22 49 21 301; fax:+ 48 22 49 21 309; strona internetowa: https://smz.ezdrowie.gov.pl lub Roche Polska Sp. z o.o., ul. Domaniewska 28, 02-672 Warszawa, tel. +48 22 345 18 88, fax +48 22 345 18 74 lub za pomocą formularza zgłoszeniowego znajdującego się pod adresem internetowym www.roche.pl/portal/pl/zglaszanie_dzialan_niepozadanych.

▼   This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for information on the reporting of suspected adverse reactions or report to your local Roche Drug Safety contact at: https://www.roche.com/solutions/pharma/safety-reporting

Roche Polska Sp. z o.o.
02-672 Warszawa, ul. Domaniewska 28
tel. (22) 345 18 88, fax (22) 345 18 74
www.roche.pl

Aktualna Charakterystyka Produktu Leczniczego Vabysmo jest dostępna na stronie https://www.roche.pl

Reference: SmPC, European Medicines Agency (EMA):
https://www.ema.europa.eu/en/documents/product-information/vabysmo-epar-product-information_en.pdf

Date of the website preparation: May 2024

M-PL-00003520